VANCOUVER, Oct. 25, 2013 /PRNewswire/ - Augurex Life Sciences Corp. announced today the expansion of key data related to its innovative 14-3-3eta biomarkers with scheduled presentations next week at the prestigious American College of Rheumatology Annual Meeting, taking place at the San Diego Convention Center, October 25-30, 2013. World-leading investigators will present data, including a late-breaking study, describing 14-3-3eta’s clinical utility for rheumatoid arthritis (RA) patient management.
Together with its clinical collaborators, Augurex has presented data at the annual meetings of the American College of Rheumatology and the European League Against Rheumatism over the past 4 years describing its panel of 14-3-3eta blood tests. These measure various aspects and forms of the 14-3-3eta protein and inform RA diagnosis, prognosis and therapy monitoring along the disease course. The field of rheumatology is moving towards early identification and treatment of RA to improve patient clinical outcomes of this otherwise chronic and debilitative autoimmune disease. The schedule for 14-3-3eta presentations at the San Diego Convention Center is as follows.
| Title | Date/Time | Location |
| 91% of Early RA Patients are Positive for Serum 14-3-3eta or its Auto-Antibodies (Abstract 1786) Presenter: W. P. Maksymowych | Oral Presentation Oct. 28, 4:30p-6:00p | Hilton-Indigo D |
| Serum 14-3-3eta Precedes and Independently Predicts the Development of RA (Abstract 1389) Presenter: D. van Schaardenburg | Oct. 28, 8:30a-4:00p | Exhibit Hall B2-C-D |
| 14-3-3eta and its Auto-Antibodies Predict Response to Anti-TNF Therapy (Abstract 1315) Presenter: W. P. Maksymowych | Oct. 28, 8:30a-4:00p | Exhibit Hall B2-C-D |
| Chaperonin Protein 14-3-3n (eta) in Rheumatoid Arthritis and Arthritogenic Viral Infections Presenter: S. J. Naides (Quest Diagnostics) | Oct. 28, 8:30a-4:00p | Exhibit Hall B2-C-D |
| Serum 14-3-3eta Marks RA Development in Arthralgia and Radiographic Progression in Early RA Patients (Abstract L13) Presenter: D. van Schaardenburg | Late-Breaking Oct 27- Oct 29, 8:30a-4:00p | Exhibit Hall B2-C-D |
In April 2013, Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, introduced two lab-developed tests to clinicians and patients in the United States based on an exclusive license agreement with Augurex to the 14-3-3eta marker. The new services aid the early diagnosis of RA, with one test service providing results of 14-3-3eta blood levels, while a comprehensive panel provides results of blood levels of 14-3-3eta as well as the conventional RA markers cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor (RF).
Augurex expects 14-3-3eta to soon be available to clinicians and patients in Canada and other major market countries through regional partnerships with leading diagnostic companies.
SOURCE Augurex Life Sciences Corp.
VANCOUVER, Oct. 25, 2013 /PRNewswire/ - Augurex Life Sciences Corp. announced today the expansion of key data related to its innovative 14-3-3eta biomarkers with scheduled presentations next week at the prestigious American College of Rheumatology Annual Meeting, taking place at the San Diego Convention Center, October 25-30, 2013. World-leading investigators will present data, including a late-breaking study, describing 14-3-3eta’s clinical utility for rheumatoid arthritis (RA) patient management.
Together with its clinical collaborators, Augurex has presented data at the annual meetings of the American College of Rheumatology and the European League Against Rheumatism over the past 4 years describing its panel of 14-3-3eta blood tests. These measure various aspects and forms of the 14-3-3eta protein and inform RA diagnosis, prognosis and therapy monitoring along the disease course. The field of rheumatology is moving towards early identification and treatment of RA to improve patient clinical outcomes of this otherwise chronic and debilitative autoimmune disease. The schedule for 14-3-3eta presentations at the San Diego Convention Center is as follows.
| Title | Date/Time | Location |
| 91% of Early RA Patients are Positive for Serum 14-3-3eta or its Auto-Antibodies (Abstract 1786) Presenter: W. P. Maksymowych | Oral Presentation Oct. 28, 4:30p-6:00p | Hilton-Indigo D |
| Serum 14-3-3eta Precedes and Independently Predicts the Development of RA (Abstract 1389) Presenter: D. van Schaardenburg | Oct. 28, 8:30a-4:00p | Exhibit Hall B2-C-D |
| 14-3-3eta and its Auto-Antibodies Predict Response to Anti-TNF Therapy (Abstract 1315) Presenter: W. P. Maksymowych | Oct. 28, 8:30a-4:00p | Exhibit Hall B2-C-D |
| Chaperonin Protein 14-3-3n (eta) in Rheumatoid Arthritis and Arthritogenic Viral Infections Presenter: S. J. Naides (Quest Diagnostics) | Oct. 28, 8:30a-4:00p | Exhibit Hall B2-C-D |
| Serum 14-3-3eta Marks RA Development in Arthralgia and Radiographic Progression in Early RA Patients (Abstract L13) Presenter: D. van Schaardenburg | Late-Breaking Oct 27- Oct 29, 8:30a-4:00p | Exhibit Hall B2-C-D |
In April 2013, Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, introduced two lab-developed tests to clinicians and patients in the United States based on an exclusive license agreement with Augurex to the 14-3-3eta marker. The new services aid the early diagnosis of RA, with one test service providing results of 14-3-3eta blood levels, while a comprehensive panel provides results of blood levels of 14-3-3eta as well as the conventional RA markers cyclic citrullinated peptide (CCP) antibodies and rheumatoid factor (RF).
Augurex expects 14-3-3eta to soon be available to clinicians and patients in Canada and other major market countries through regional partnerships with leading diagnostic companies.
SOURCE Augurex Life Sciences Corp.
